Did Lilly Overcome US Price Pressures In Last Quarter? Investors Await Answer

With business heavily dependent on sales revenue from Medicare Part D and other US government programs, Lilly will be expected to narrow the gap between US prescription and sales growth.

Medicare Part D text on calculator with prescription pills in bottle on American money
Lilly is more reliant on sales from Medicare Part D than its peers

One of the most notable characteristics of Eli Lilly & Co.’s third quarter 2019 sales and earnings report last October was that US prescription growth of top-sellers like Trulicity and Taltz was inhibited significantly by price factors, including the fact that the Indianapolis pharma is dependent on government-insured patients for a high portion of its domestic revenues.

As Lilly reports its fourth quarter and full-year 2019 financials on 30 January, investors will be listening to hear if...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.